Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance

Evidence of antibody isotype/subtype switching may provide prognostic value regarding the state of immune responses to therapeutic proteins, e.g. anti-factor VIII (FVIII) antibodies that develop in many hemophilia A patients, clinically termed “inhibitors”. A sensitive, high- information-content surface plasmon resonance (SPR) assay has been developed to quantify IgG subtype distributions and the domain specificity of anti-drug antibodies. Plasma samples from 22 subjects with an allo- or auto-immune reaction to FVIII were analyzed. Pre-analytical treatment protocols were developed to minimize non-specific binding and specific matrix interference due to von Willebrand factor-FVIII interactions. The dynamic range for IgG quantification was 0.2–5 µg/ml (∼1–33 nM), allowing characterization of inhibitor-positive samples. Subtype-specific monoclonal antibodies were used to quantify the IgG subtype distribution of FVIII-specific antibodies. Most samples obtained from multiply-infused inhibitor subjects contained IgG4 antibodies. Several distinct phenotypes were assigned based on the IgG subtype distribution: IgG1, IgG4, IgG1 & IgG4, and IgG1, IgG2 & IgG4. An IgG1-only response was found in mild/moderate HA subjects during early FVIII infusions, and analysis of serial samples followed antibody class switching as several subjects’ immune responses developed. Competition studies utilizing a recombinant FVIII-C2 domain indicated 40–80% of FVIII-specific antibodies in most samples were directed against this domain.

[1]  A. Neff,et al.  Development of factor VIII inhibitors in two patients with moderate haemophilia A , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  A. Rademaker,et al.  Alloantibodies to factor VIII in haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  M. M. D. de Bracco,et al.  A flow cytometry evaluation of anti‐FVIII antibodies: correlation with ELISA and Bethesda assay , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  K. Lewis,et al.  Comparison of the ability of wild type and stabilized human IgG(4) to undergo Fab arm exchange with endogenous IgG(4)in vitro and in vivo. , 2009, Molecular immunology.

[5]  P. Parren,et al.  Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo , 2009, Nature Biotechnology.

[6]  K. Mann,et al.  Quantitation of anti-factor VIII antibodies in human plasma. , 2009, Blood.

[7]  A. Thompson,et al.  B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses , 2009, Clinical reviews in allergy & immunology.

[8]  J. Oger,et al.  A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[9]  U. Dietrich,et al.  Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. , 2008, Molecular immunology.

[10]  S. Meeks,et al.  Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. , 2008, Blood.

[11]  J. Voorberg,et al.  IgG subclasses of anti‐FVIII antibodies during immune tolerance induction in patients with hemophilia A , 2008, British journal of haematology.

[12]  E. Bergmann-Leitner,et al.  Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies , 2008, Malaria Journal.

[13]  C. Granier,et al.  Simultaneous detection and epitope mapping of anti-factor VIII antibodies , 2008, Thrombosis and Haemostasis.

[14]  J. Oldenburg,et al.  The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis , 2008, Thrombosis and Haemostasis.

[15]  S. Meeks,et al.  Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. , 2007, Blood.

[16]  P. Parren,et al.  Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.

[17]  G. Auerswald,et al.  Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. , 2007, Blood.

[18]  K. Pratt,et al.  ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  J. Parkkinen,et al.  A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance , 2006, Vox sanguinis.

[20]  A. Jungbauer,et al.  Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays. , 2006, Journal of immunological methods.

[21]  Kouhei Tsumoto,et al.  Effective elution of antibodies by arginine and arginine derivatives in affinity column chromatography. , 2005, Analytical biochemistry.

[22]  R. Sharifian,et al.  Comparative Measurement of Anti-Factor VIII Antibody by Bethesda Assay and ELISA Reveals Restricted Isotype Profile and Epitope Specificity , 2005, Acta Haematologica.

[23]  C. Granier,et al.  Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor , 2003, Thrombosis and Haemostasis.

[24]  D. Mohanty,et al.  An ELISA Assay for the Detection of Factor VIII Antibodies – Comparison with the Conventional Bethesda Assay in a Large Cohort of Haemophilia Samples , 2002, Acta Haematologica.

[25]  M. Reding,et al.  Distribution of Th1- and Th2-induced Anti-factor VIII IgG Subclasses in Congenital and Acquired Hemophilia Patients , 2002, Thrombosis and Haemostasis.

[26]  A. Somogyi,et al.  Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time‐course studies , 2001, British journal of haematology.

[27]  J. Healey,et al.  Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. , 2000, Blood.

[28]  M F Hoylaerts,et al.  Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. , 1998, Blood.

[29]  H. Kikuta,et al.  Measles virus-specific immunoglobulin G subclass response in serum and cerebrospinal fluid. , 1997, Clinical and diagnostic virology.

[30]  P. Lollar.  Analysis of Factor VIII Inhibitors Using Hybrid Human/Porcine Factor VIII , 1997, Thrombosis and Haemostasis.

[31]  I. Scharrer,et al.  The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. , 1997, Blood.

[32]  G. E. Gilbert,et al.  Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. , 1995, Blood.

[33]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[34]  S. Morrison,et al.  Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies. , 1993, Journal of immunological methods.

[35]  J. Arnout,et al.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. , 1993, Blood.

[36]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[37]  J. Aznar,et al.  Immunological characterization of factor VIII inhibitors by a sensitive micro-ELISA method. , 1990, Thrombosis research.

[38]  C. Fulcher,et al.  Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. , 1989, Blood.

[39]  C. Fulcher,et al.  Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. , 1988, Blood.

[40]  P. Lollar,et al.  Association of the factor VIII light chain with von Willebrand factor. , 1988, The Journal of biological chemistry.

[41]  C. Fulcher,et al.  FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. , 1987, Blood.

[42]  R. Aalberse,et al.  Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. , 1983, Journal of immunology.

[43]  D. Green,et al.  Proceedings: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.